# ABSTRACT

Industry in Indonesia faces increasingly heavy and broad competition as it enters the current era of globalization. Therefore the industries in Indonesia, especially the pharmaceutical industry need to continuously spur the productivity of each of their resources in order to be able to compete globally and be able to produce quality products.

The research method used is descriptive. Secondary data sources in the form of financial statements for the period 2012-2017 from companies in the Pharmaceutical Industry obtained from the official website of each company. This study aims to analyze the performance and financial health of companies in the pharmaceutical industry listed on the Indonesia Stock Exchange (IDX) in 2012-2017. The method used is the Du Pont System method and the Altman Z-Score model.

The research data is secondary data obtained from the company's financial statements published by the IDX.

The results of this study indicate that: PT. Merck Tbk has the highest average ROI compared to other companies. Z-Score, PT. Merck Tbk is also the highest compared to other companies. While other companies, namely PT. Darya Varia Laboratoria Tbk, PT. Pyridam Farma Tbk and PT. Tempo Scan Pacific Tbk has a pretty good average value of ROI. But the average value of ROI of PT. Indofarma (Persero) Tbk and PT. Merck Sharp Dohme Pharma Tbk is at the lowest value compared to other companies. Judging from the Altman Z-Score model the six companies studied had a healthy category average, even though PT. Indofarma (Persero) Tbk and PT. Merck Sharp Dohme Pharma Tbk was in the gray category in a certain year.

Keywords: ROI, Du Pont System, Altman Z-Score, Financial Report